Fig. 6

CD200Fc alleviates adult hippocampal neurogenesis impairment induced by CSDS. A Experimental timelines for CSDS procedure, AAV–CD200 injection and behavioral testing. B Hippocampal neurogenesis process, including cellular types and their specific markers. C Representative immunostaining for GFAP (blue)/SOX2 (red) in the DG of control and CSDS group with or without AAV–CD200. Scale bars: 40 μm. D, E Statistical graph for the numbers of GFAP⁺ (D) and GFAP⁺ SOX2⁺ (E) cells in the DG of control and CSDS group with or without AAV–CD200 (n = 3 mice per group, two-way ANOVA with Fisher’s LSD test). F Representative immunostaining for Ki67 (green)/GFAP (red) in the DG of control and CSDS group with or without AAV–CD200. Scale bars: 40 μm. G, H Statistical graph for the numbers of Ki67⁺ (G) and Ki67⁺ GFAP⁺ (H) cells in the DG of control and CSDS group with or without AAV–CD200 (n = 3 mice per group, two-way ANOVA with Fisher’s LSD test). I Representative immunostaining for BrdU (red)/DCX (green)/DAPI (blue) in the DG of control and CSDS group with or without AAV–CD200. Scale bars: 40 μm. J, K Statistical graph for the number of BrdU⁺ (J) and BrdU⁺ DCX⁺ (K) cells in the DG of control and CSDS group with or without AAV–CD200 (n = 3–5 mice per group, two-way ANOVA with Fisher’s LSD test). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Ctrl, control. See Additional file 1: Table S2 for detailed statistical information